Can a single injection curb blood loss in fibroid surgery?

NCT ID NCT07746349

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests whether injecting a diluted solution of terlipressin, a drug that narrows blood vessels, under the outer layer of a uterine fibroid before removal can reduce blood loss during myomectomy surgery. Women scheduled for myomectomy will be randomly assigned to receive either the terlipressin injection or a placebo (salt water), and neither they nor the surgical team will know which they received. The main goal is to measure the amount of blood lost during surgery in each group, with additional checks on hemoglobin changes, transfusion needs, and surgery duration.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
terlipressin (a vasoconstrictor drug) injected under the fibroid capsule before removal
What this could lead to
If effective, this approach could reduce bleeding during fibroid surgery, lowering the need for transfusions and improving surgical safety.
What could go wrong
This is a small, early-stage trial, and the benefit may be modest or not confirmed. Terlipressin can cause side effects like high blood pressure or reduced blood flow to organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEIOMYOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.